JPRN-jRCT2080220017未知3 期
Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 <= 19age old（—）
入选标准
- •Inclusion criteria
- •1. Patients with sJIA diagnosed according to the revised 1997 ILAR (the International league of associations for Rheumatology) criteria
- •2. 2 and over Age and below 20
排除标准
- 未提供
研究者
相似试验
未知
3 期
Phase 3 clinical study of RM-003 in patients with homocystinuriaHomocystinuria, described as the following casescystathionine beta-synthase deficiency(CBS), 5,10-methylenetetrahydrofolate reductase deficiency, defects in cobalamin metabolismJPRN-jRCT2080221773ReqMed Company, Ltd.8
已完成
1 期
PhaseI/IIstudy of AMR in elderly patients with small-cell lung cancer previously treated with platina-based chemotherapysmall-cell lung cancerJPRN-UMIN000005606ung Oncology Group in Kyushu, Japan (LOGIK)38
进行中（未招募）
不适用
Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®Patients with low or moderate clinical probability for pulmonary embolism and positive or negative CTA for pulmonary embolism after CT and sonographic examination for deep venous thrombosis.EUCTR2005-004325-25-DEAdministration management, Ludwig-Maximilians-University of Munich20
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-BESCS Boehringer Ingelheim Comm. V515
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-ATBoehringer Ingelheim RCV GmbH & Co KG250